Allezoe Medical Holdings (ALZM) Acquiring Technology To "See and Treat" HPV

BOCA RATON, FLORIDA--(Marketwire - Sept. 20, 2011) - Allezoe Medical Holdings, Inc. ALZM announces today that it has agreed to acquire technology that enables healthcare providers to "see and treat" the most common sexually transmitted infection and a cause of cervical cancer, Human Papillomavirus (HPV). Aequorea Vision Medical, based in Texas, developed the patent pending medical technology and Allezoe has acquired the pending patent application and all related intellectual property as well as the existing prototype models of the device. Allezoe plans to form a new wholly-owned subsidiary to complete the development of the device, obtain the required regulatory approvals and clearances, and begin marketing the device and technology.

Approximately 20 million Americans are currently infected with HPV and it is expected that 5.5 million more will contract the HPV through sexual contact each year. There are more than 40 types of HPV that can infect the genital areas of men and women, causing genital warts or infecting the mouth and throat.

The need for better treatments for HPV is clear. According to Time.com, approximately 40% of girls become infected with HPV within two years of becoming sexually active. By age 50, 80% of women have had the virus at some point, though many have no symptoms. While asymptomatic patients may not know to seek treatment, the technology, which can be incorporated into a regular visit, will allow healthcare staff to identify a problem before it becomes more serious. Currently, HPV causes 70% of cervical cancer cases; cervical cancer is diagnosed in 11,000 women per year in the U.S. alone.

The light-based exam device Allezoe is acquiring instantly identifies HPV lesions with 98% accuracy, enabling providers to see cell damage and then treat the patient on the spot. The technology is a great improvement upon the discomfort of a traditional 75-year old Pap test as well as the related delays in confirming an HPV diagnosis. It also has important implications for healthcare abroad and in poorer nations where patients do not have the luxury of making repeated visits to a clinic or waiting several days for a PAP smear report from a distant laboratory. HPV has recently received much attention due to the public debate regarding the safety of the HPV vaccines. Regardless of one's stance on that issue, the technology Allezoe will be acquiring allows a patient to be screened for damage that may have occurred in the window before the vaccine was received.

Allezoe's CEO Michael Gelmon says, "The prevalence and rise of HPV needs to be met with technology that can address it swiftly, proactively, and most of all, safely. This is a solution that is not only efficient but incredibly cost effective. The immense opportunities presented by this technology bring us all one step closer to better health."

In addition to HPV, the human virus, the technology has veterinary applications to Bovine Papillomavirus, which is believed to be the cause of Equine Sarcoid (skin tumors). Early diagnosis and the flexibility the technology provides for an on-site diagnosis could prevent transmission among horses and cattle living in close quarters.

Safe Harbor Statement

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21 E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that these forward-looking statements involve uncertainties and risk that could cause actual performance and results of operations to differ materially from those anticipated. These risks are set forth in the Company's most recently filed form 10-K and Form 10-Q reports. The Company assumes no obligation to update the statements contained in this release except as required by applicable securities disclosure rules.

The Company's SEC filings are available at http://www.sec.gov.